Search

Royalty Pharma PLC (Class A)

Suletud

SektorTervishoid

69.29 0.51

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

68.11

Max

69.41

Põhinäitajad

By Trading Economics

Sissetulek

440M

145M

Müük

16M

690M

P/E

Sektori keskmine

44.948

68.089

Aktsiakasum

1.21

Dividenditootlus

1.37

Kasumimarginaal

21.014

Töötajad

100

EBITDA

181M

357M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+2.46% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

1.37%

1.98%

Järgmine tulemuste avaldamine

10. veebr 2027

Järgmine dividendimakse kuupäev

10. dets 2026

Turustatistika

By TradingEconomics

Turukapital

1.1B

40B

Eelmine avamishind

68.78

Eelmine sulgemishind

69.29

Royalty Pharma PLC (Class A) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. nov 2026, 21:07 UTC

Event
News

Royalty Pharma PLC has declared an ex-dividend of $0.235 per share, with shares advancing amid strong performance in the Pharmaceuticals sub-sector.

12. nov 2026, 20:36 UTC

News

Shares of Royalty Pharma PLC are declining after the company raised its 2026 guidance, despite a clinical setback for Pelacarsen.

11. nov 2026, 23:16 UTC

Royalty Pharma PLC is trading roughly flat in after-market hours, recovering slightly from an earlier low amid strong monthly performance.

10. nov 2026, 21:07 UTC

Royalty Pharma PLC shares are modestly higher, reaching the upper end of their one-month range as the broader market nears 1% cumulative returns since Monday.

9. nov 2026, 21:03 UTC

Royalty Pharma PLC shares are rising amid high trading volume, having advanced since Friday and trading well above its 20-day moving average.

6. nov 2026, 22:51 UTC

Royalty Pharma PLC shares advanced in after-hours trading, reaching a peak return amid strong performance and significantly above their 20-day moving average.

5. nov 2026, 21:08 UTC

Royalty Pharma PLC traded near unchanged, retracing from a notable high reached earlier in the session, while remaining above its 20-day moving average.

4. nov 2026, 21:04 UTC

Correlated Moves
News

Royalty Pharma PLC raised its full-year 2026 guidance for portfolio receipts to $3.50B-$3.55B after reporting strong Q3 results with $890M in receipts.

3. nov 2026, 21:07 UTC

Royalty Pharma PLC shares are declining, pulling back from an earlier gain but remaining above the 20-day moving average and near the upper end of its one-month range.

30. okt 2026, 20:03 UTC

Royalty Pharma PLC shares are advancing, significantly above their 20-day moving average and near the upper end of their one-month range.

29. okt 2026, 20:07 UTC

Correlated Moves

Royalty Pharma PLC shares are higher, supported by strong momentum in the broader market and gains in key holdings within the XLV ETF during earnings season.

28. okt 2026, 20:07 UTC

Royalty Pharma PLC shares are declining, following a broader market trend lower since Tuesday, despite stabilizing somewhat after an earlier drop.

27. okt 2026, 20:01 UTC

Royalty Pharma PLC is trading modestly higher, supported by a notable increase in market volume and remaining significantly above its 20-day moving average.

26. okt 2026, 22:16 UTC

Royalty Pharma PLC is trading modestly higher in after-market hours, continuing its performance from Monday's close and remaining well above its 20-day moving average.

23. okt 2026, 20:07 UTC

Shares of Royalty Pharma PLC are advancing, showing a slight gain since Thursday's close and recovering to near its highest point during Friday's trading session.

22. okt 2026, 20:02 UTC

Royalty Pharma PLC is gaining amid a broader market downturn, diverging from the recent upward momentum observed in prior sessions.

21. okt 2026, 20:41 UTC

Royalty Pharma PLC is experiencing a notable decline in after-market trading, moving lower since Wednesday's close and trading at the lower end of today's range.

20. okt 2026, 22:46 UTC

Royalty Pharma PLC's shares advanced in after-market hours on Tuesday, remaining just above the previous close and 7.13% above its 20-day moving average.

19. okt 2026, 20:07 UTC

Royalty Pharma PLC shares are declining, hitting a midday low after an early peak.

16. okt 2026, 20:02 UTC

News

Royalty Pharma PLC declared a quarterly dividend of $0.235 per Class A share, payable on December 10, 2026, to shareholders of record as of November 13, 2026.

15. okt 2026, 20:07 UTC

Correlated Moves

Royalty Pharma PLC shares advanced, supported by broader market strength, while the Health Care Select Sector SPDR ETF reached a record high.

14. okt 2026, 20:02 UTC

Royalty Pharma PLC is advancing during Wednesday's market hours, continuing its upward trajectory since Tuesday's close with unusually high trading volume.

13. okt 2026, 20:02 UTC

Royalty Pharma PLC shares fell sharply, trading near the low end of their one-month range after an initial rebound earlier in the session.

12. okt 2026, 20:06 UTC

Royalty Pharma PLC is advancing, reflecting a strong performance since Friday's close, with today's price peaking in the early afternoon before settling slightly lower.

9. okt 2026, 21:01 UTC

Royalty Pharma PLC shares traded lower in after-market hours, remaining below their 20-day moving average and near the lower end of their one-month range.

8. okt 2026, 20:13 UTC

Royalty Pharma PLC shares advanced modestly during after-market hours on Thursday, holding steady with no notable fluctuations since the market closed.

7. okt 2026, 19:35 UTC

News

Royalty Pharma PLC shares advanced modestly after Morgan Stanley raised its price target to $67.00 from $65.00 while maintaining an Overweight rating.

6. okt 2026, 20:12 UTC

Royalty Pharma PLC is trading modestly higher in after-market hours, maintaining a steady position below its 20-day moving average and near the lower end of its one-month range.

5. okt 2026, 20:02 UTC

Royalty Pharma PLC shares fell sharply, continuing a downward trend amid broader pharmaceutical sector weakness and reflecting unusually high market volume.

2. okt 2026, 20:07 UTC

Royalty Pharma PLC shares fell sharply, continuing a downward trend and hitting a session low just before market close, significantly below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Royalty Pharma PLC (Class A) Prognoos

Hinnasiht

By TipRanks

2.46% tõus

12 kuu keskmine prognoos

Keskmine 70.667 USD  2.46%

Kõrge 78 USD

Madal 63 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Royalty Pharma PLC (Class A) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat